Difference between revisions of "Irinotecan liposome (Onivyde)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "[[Media:" to "[[File:")
Line 1: Line 1:
 
==General information==
 
==General information==
Class/mechanism: Topoisomerase I inhibitor with [[Irinotecan (Camptosar)|irinotecan]] contained within a liposomal sphere.  Irinotecan interferes with topoisomerase I's normal action of relieving torsional strain in DNA by creating reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I & DNA complex and interfere with ligation of these single-strand breaks. Failure to repair these breaks eventually leads to double-strand DNA damage, which disrupts cell proliferation and leads to cell death.  In mouse models, 5 times lower doses of liposomal irinotecan were able to achieve similar intratumoral exposure levels of SN-38 as compared to irinotecan HCl.<ref name="insert">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207793lbl.pdf Irinotecan liposome (Onivyde) package insert]</ref><ref>[[Media:Irinotecanliposomal.pdf | Irinotecan liposome (Onivyde) package insert (locally hosted backup)]]</ref><ref>[https://www.onivyde.com/ Onivyde manufacturer's website]</ref><ref>[http://merrimackpharma.com/solutions/pipeline/mm-398 Merrimack Pharmaceuticals's MM-398 website]</ref>
+
Class/mechanism: Topoisomerase I inhibitor with [[Irinotecan (Camptosar)|irinotecan]] contained within a liposomal sphere.  Irinotecan interferes with topoisomerase I's normal action of relieving torsional strain in DNA by creating reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I & DNA complex and interfere with ligation of these single-strand breaks. Failure to repair these breaks eventually leads to double-strand DNA damage, which disrupts cell proliferation and leads to cell death.  In mouse models, 5 times lower doses of liposomal irinotecan were able to achieve similar intratumoral exposure levels of SN-38 as compared to irinotecan HCl.<ref name="insert">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207793lbl.pdf Irinotecan liposome (Onivyde) package insert]</ref><ref>[[File:Irinotecanliposomal.pdf | Irinotecan liposome (Onivyde) package insert (locally hosted backup)]]</ref><ref>[https://www.onivyde.com/ Onivyde manufacturer's website]</ref><ref>[http://merrimackpharma.com/solutions/pipeline/mm-398 Merrimack Pharmaceuticals's MM-398 website]</ref>
 
<br>Route: IV
 
<br>Route: IV
 
<br>Extravasation: no information available
 
<br>Extravasation: no information available

Revision as of 23:27, 19 September 2021

General information

Class/mechanism: Topoisomerase I inhibitor with irinotecan contained within a liposomal sphere. Irinotecan interferes with topoisomerase I's normal action of relieving torsional strain in DNA by creating reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I & DNA complex and interfere with ligation of these single-strand breaks. Failure to repair these breaks eventually leads to double-strand DNA damage, which disrupts cell proliferation and leads to cell death. In mouse models, 5 times lower doses of liposomal irinotecan were able to achieve similar intratumoral exposure levels of SN-38 as compared to irinotecan HCl.[1][2][3][4]
Route: IV
Extravasation: no information available

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code names: MM-398, MM398, PEP-02, PEP02
  • Brand name: Onivyde

References